Pierre Fabre Medicament

Company snapshot

PIERRE FABRE MEDICAMENT PRODUCTION is a pharmaceuticals company based out of 45 PLACE ABEL GANCE, BOULOGNE BILLANCOURT, France.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Pierre Fabre Medicament. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Pierre Fabre Medicament.

1. Jun 8, 2026 Clinical update

   PFL721CI101 — Phase 2

2. Jun 8, 2026 Clinical update

   V00018PC303 — Phase 3

3. Jun 8, 2026 Clinical update

   KN-8701/KIN2787CI101 — Phase 1

4. Jun 8, 2026 Clinical update

   F60087CI101 — Phase 2

5. Jun 8, 2026 Clinical update

   EBVALLO — Phase 2

View all clinical trial activity →

• What is Pierre Fabre Medicament?

  PIERRE FABRE MEDICAMENT is a pharma organization headquartered in LAVAUR, FR. Primary therapeutic focus areas include Breast Cancer, Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease, X-linked hypohidrotic ectodermal dysplasia (XLHED), Cessation of smoking

• Is Pierre Fabre Medicament publicly traded?

  Pierre Fabre Medicament appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Pierre Fabre Medicament develop or market?

  We link 13 drug profile(s) where Pierre Fabre Medicament is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/pierre-fabre-medicament#company-drugs.

• What are the latest developments for Pierre Fabre Medicament?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Pierre Fabre Medicament focus on?

  Pierre Fabre Medicament focuses on Breast Cancer, Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease, X-linked hypohidrotic ectodermal dysplasia (XLHED) based on our analysis of their pipeline programs and drug development activities.